MPNErare2017 Session 3 Ocular Melanoma 7th October 2017 Leiden
Systemic treatment of metastasized uveal melanoma Ellen Kapiteijn, medical oncologist, LUMC 7 oktober 2017
Disclosures Advisory boards Roche, BMS, MSD, Novartis, SIRTEX, Delcath
Background UM
• Low incidence (0.6-0.7 pts/100.000/yr) • Primary treatment aims for curation: radiotherapy (ruthenium), proton beam irradiation or enucleation • Difference with skin melanoma with regard to molecular biology: GNA11 or GNAQ mutations (approx. 90% in metastasized setting), no braf mutations, low mutational load, low PDL1-expression
Background UM
• Metastases: < 5 yr: 30% of the pts < 15 jr: 50% of the pts • Metastases mostly to liver (up to 90% of the pts), lungs (30%), bone (23%) and skin (17%) • Limited prognosis in case of metastatic disease • 1980-2008: 28 phase I-II studies with systemic therapy (mostly chemotherapy): no survival benefit
Metastasized UM
Immunotherapy
Anti-CTLA4 in metastatic UM
Author
Site(s)
N
Response
3 mnth DCR*
PFS (mnths)
OS (mnths)
Kelderman ‘13
Neth
22
1/14 (7%)
2/14 (14%)
2.9
5.2
Luke ‘13
US
39
2/39 (5%)
18/39 (46%)
NR**
9.6
Maio ‘13
Italy
83
4/83 (5%)
29/83 (35%)
3.6
6.0
Piulats ‘14
Spain
32
2/25 (8%)
NR**
NR**
9.8
Zimmer ‘15
Germany 53
0/34 (0%)
16/34 (47%)
2.8
6.8
9/195 (5%)
65/170 (38%)
229 *DCR: disease control rate **NR: not reported
6
Insert > Header & footer
7-Okt.-17
Anti-PD1 or anti-PDL1 in metastatic UM Author
Agent
Site(s)
N
Prior Ipi
Responses
PFS (mnths)
OS (mnths)
Algazi
Pembro, Nivo, Atezo
US, Spain
58
36 (62%)
4%
2.8
6.8
Karydis
Pembro
UK
25
25 (100%)
8%
3.0
Not reached
PipernoNeumann
Pembro, Nivo
Paris
21
NR*
5%
2.6
NR*
Kottschade
Pembro
Mayo
10
10 (100%)
30%
4.1
NR*
Vd Kooij
Pembro, Nivo
Neth
17
NR*
0%
2.3
9.6
131
8/131 (6%)
*NR: not reported
7
Insert > Header & footer
7-Okt.-17
Conclusions checkpoint-inhibitors in metastatic UM
•
International case-series: CTLA4, PD-1 and PD-L1 antibodies rarely confer durable remissions in patients with metastatic uveal melanoma. Due to low mutational load and/or less PDL1-expression?
•
Several studies ongoing
•
New clinical trials are necessary: combination-therapies?
8
Insert > Header & footer
7-Okt.-17
IMCgp100 Shoustari et al SMR, nov 2016 A Phase I study of IMCgp100, a soluble HLA-A2 restricted gp100-specific T cell receptor-CD3 therapeutic with solid tumour activity in pts with advanced uveal melanoma • 15 pts were reported • Durable objective responses were observed: disease control rate was 53% at 16 wks, and 40% at 24 wks. A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma will start Q4 2017 / Q1 2018
TIL-therapy in uveal melanoma. Chandran et al, Lancet Oncology 2017
10
Insert > Header & footer
7-Okt.-17
Metastatic UM
Targeted therapy
AEB071- study (PKC-inh), Piperno-Neumann et al, ASCO â&#x20AC;&#x2DC;14 COEB071X2102 - AS CO P os ter - Cut-off date: 07AP R2014 Figure 14.2-1.3 (P age 1 of 1)
Figure. Best percentage change from in sum of longest diameters Bes t % change from bas eline baseline in s um of longes t diameters for all patients Full analys is s et of target lesions for all patients (N=118/141; full analysis set) n/N (%) = 118/141 (83.69%) 100
Bes t %change from bas eline
80 60 40 20 0 -20 -40
* * **** ** *
* *** ***** ******** ******** * * * *** *** ******** ****** ** *** *
* ****** ******* * **** * * * *
-60 -80 -100
*Progression-free survival event. n: number of subjects with a baseline and at least one post-baseline assessment of target lesions based on local investigator assessment.
**
*
Phase I study with AEB071 (PKC-inh) + MEK162
Study preliminary closed due to too much toxicity
Phase II trial selumetinib (MEK-inhibitor)
Phase III trial selumetinib (MEK-inhibitor)
LXS196 (PKC-inhibitor) A Phase I/II, multi-center, open-label, study of LXS196, an oral protein kinase C inhibitor in patients with metastatic uveal melanoma: 4 centers worldwide, Jan 2016 â&#x20AC;&#x201C; Sept 2017, 67 pts included. Results will be presented at SMR 2017.
New combination study LXS196 (PKC-inh) + HDM-201 (MDM2-inh) A Phase I/II, multi-center, open-label, study of LXS196 and HDM-201 in patients with metastatic uveal melanoma: 5 centers worldwide, start Q4 2017 / Q1 2018.
18
Insert > Header & footer
7-Okt.-17
Ongoing trials in metastatic UM Mechanism
Agent
Phase
Sponsor / Lead center
Clinicaltrials.gov ID
Checkpoint blockade
Ipilimumab/ Nivolumab
II
MDACC
NCT01585194
Pembrolizumab + Entinostat
II
Vastra Gotaland Region, Sweden
NCT02697630
Ipilimumab / Nivolumab + radioembolization
0
CPMC
NCT02913417
TILs
Cellular Adoptive Immunotherapy + ipilimumab
I
MDACC
NCT03068624
T cell redirection
IMCgp100
II
Immunocore
NCT03070392
T-cell receptor
T-cel Receptor Gene Therapy
I/IIa
AvL
NCT02654821
19
Insert > Header & footer
7-Okt.-17
Ongoing trials in metastatic UM Mechanism
Agent
Phase
Sponsor/Lead center
MEK-inhibitor
Intermittent selumetinib
Ib
Columbia, several NCT02768766 other US centers
PKC-inhibitor
AEB071+BYL71 9
Ib
Columbia, several NCT02273219 other US centers
CSF-1R, Kit and Flt3 PLX2853 inhibitor
Ib/IIa (incl. other tumor types)
HHS, Arizona
NCT03297424
PEGylated arginine ADI-PEG 20 deiminase
I (incl. other tumor types)
CECM, London
NCT02029690
20
Insert > Header & footer
Clinicaltrials.gov ID
7-Okt.-17
Conclusions •
No proven effective systemic treatment options yet in metastatic UM
•
Increased insight in the molecular biology of uveal melanoma has led to studies with specific targeted agents (PKC- and MEK-inhibitors), also studies with immunotherapy ongoing (checkpoint-inhibitors, TILtherapy, IMCgp100)
•
New (combination)-studies are very important for the development of effective treatment options
Thank you for your attention!
For contact: h.w.kapiteijn@lumc.nl
Genetic testing for uveal melanoma Helen Kalirai
Senior Research Fellow Dept. of Molecular and Clinical Cancer Medicine; University of Liverpool, UK
www.loorg.org
Chromosome 3 loss in uveal melanoma
Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R
Cancer 1998;83:354â&#x20AC;&#x201C;9
Identification of chromosome aberrations in UM
Genetic testing of UM samples Cytospin
Damato B, Groenewald C Vitreo-retinal surgery (2007)
MSA*
MLPA*
MelanA
Low risk
Choroidal melanoma Requires 10ng DNA
Choroidal melanoma Requires ≥ 100ng DNA
* MLPA kit for UM - DEKRA Certified to ISO 13485 standard; under the ‘In Vitro Diagnostic Medical Devices directive’ (98/79/EC) permitted for clinical use ** CPA-Accredited molecular pathology laboratory; internal and external quality assessment
High risk
Genetic testing of UM samples Cytospin
Damato B, Groenewald C Vitreo-retinal surgery (2007)
MLPA* Low risk
Choroidal melanoma
Post-PBR TX * MLPA kit for UM - DEKRA Certified to ISO 13485 standard; under the â&#x20AC;&#x2DC;In Vitro Diagnostic Medical Devices directiveâ&#x20AC;&#x2122; (98/79/EC) permitted for clinical use ** CPA-Accredited molecular pathology laboratory; internal and external quality assessment
High risk
Are FNAB representative of the whole UM?
Damato B, Groenewald C Vitreo-retinal surgery (2007)
Prognostication in UM
Parameters
Clinical
Age Gender Tumour Size Location Extraocular melanoma
Histomorphological Cell type Mitotic count Closed loops ‘Inflammation’ EOM
Genetic Chr. 3 loss Chr. 8 gain Chr. 6 gain
Date:
Prognostication model - LUMPO Patient's Name:
Hospital Number:
Apical part
Practitioner's Name:
Clinical
Position:
years
www.ocularmelanomaonline.org
Age
53
Sex
Male
Epithelioid cells
Large ultrasound diameter
15.1-18.0
mm
Mitotic rate /40
>7
Ultrasound thickness
9.1-12.0
mm
Monosomy 3
Yes
Ciliary body involvement*
No
Regional lymph nodes
Extraocular extension*
No
Distant metastasis
N/A
Years since treatment
0-1
First scan
0.5
Threshold for next scan
N/A
Closed PAS +ve loops
years
No
Histopathological N/A
Cytogenetic N/A
years
Accelerated Failure Time
Resetfeatures need to be taken All into account
Kaplan-Meier
Melanoma Patients
Evaluate
General Population
Impact Genetics 1100 Bennett Road â&#x20AC;&#x201C; Unit 4 Bowmanville, ON L1C 3K5 CANADA
Chromosome 8q gains are also associated with a poor prognosis
LUMPO III
Genetic testing in UM: other techniques Gene expression profiling
Tschentscher F et al. 2003
Onken et al, 2007
Incorporation of PRAME into GEP of UM. Matthew G. Field et al. Clin Cancer Res 2016;22:1234-1242
Mutation profiling â&#x20AC;&#x201C; refining uveal melanoma classification for prognosis and therapy
GNAQ/GNA11 activating mutations • Mutually exclusive mutations found in approx. 84% of UM. • Early events associated with UM development. • Clinical utility: Ø Differential diagnosis Ø Targeted therapy
GNA11 c.626A>T (Q209L) mutation in a UM specimen
BAP1 inactivating mutations • BAP1 (Chr.3p21) inactivating mutations are found in ~85% metastasising UM • Mutations associated with reduced disease free survival • Clinical utility: Ø Prognosis Ø Targeted therapy
Monosomy 3/nBAP1+ve UM represent a subset with better prognosis
SF3B1 mutations • SF3B1 mutations found mainly in D3 tumours. Associated with a late metastatic onset
EIF1AX mutations • EIF1AX mutations are associated with a good prognosis
• Mutations found in 9 -19% of all UM
• Mutations in EIF1AX reported in 19 – 24% of all UM
• Clinical utility: Ø Prognosis Ø Targeted therapy
• Clinical utility: Ø Prognosis Ø Targeted therapy
Other developments in UM genetics
Subgrouping of UM according to chromosomal alterations 80 primary UM samples
4 subgroups (Clusters): 1. Disomy 3, partial or total 6p gain 2. Disomy 3, 6p gain, partial 8q gains 3. Monosomy 3, 8q gain (median 1 extra copy) 4. Monosomy 3, 8q gain (median 3 extra copies; commonly 8q isochromosome) Caines R, Eleuteri A, Kalirai H, Fisher A, Heimann H, Damato B, Coupland SE and Taktak A. Cluster analysis of Multiplex Ligation-dependent Probe Amplification (MLPA) data in uveal melanoma: review of 602 cases. Molecular Vision, 2015; 21:1-11
Nine* significantly mutated genes in UM
*PLCB4
Subgrouping of UM according to chromosomal alterations
4 subgroups (Clusters): 1. Disomy 3, partial or total 6p gain 2. Disomy 3, 6p gain, partial 8q gains 3. Monosomy 3, 8q gain (median 1 extra copy) 4. Monosomy 3, 8q gain (median 3 extra copies; commonly 8q isochromosome)
EIFAX1 mutations
BAP1 mutations
Four transcription-based UM subgroups RNA sequencing revealed the expression of 20,531 mRNAs and processed transcripts, identified 4 consensus subgroups for mRNA
Class1B
Correlation of biological UM subsets with clinical prognosis CNA
GEP
Characteristics of Immune-Infiltrated UM
WP4: Increased understanding of molecular Characterisation changes in metastatic UM and generation of UM metastases of new target hypotheses for WP2 WP4: Increased understanding of molecular Characterisation changes in metastatic UM and generation of UM metastases of new target hypotheses for WP2
Decipher the: Decipher the: • genetic alterations • genetic alterations
• dysregulated signalling pathways
• dysregulated signalling pathways • characteristics of the UM immune landscape
• characteristics of the UM immune landscape
Thank you for your attention
Dawn
h.kalirai@liverpool.ac.uk
Dusk
Why is prognostication important in UM? Management of primary UM
Surveillance Detection of Metastases Contrast MRI CT body Biopsy Tumour board Laparoscopy
R0 resection
Operable
•
• • •
Identify “high risk” patients for more frequent and intense screening (MRI) of liver Surgical removal of isolated metastases Involvement in clinical trials Patient demand
Inoperable Chemo
Surgery
Locoregional therapy
Systemic therapy
Targeted Immune
MPNErare2017 LIVER DIRECTED THERAPY IN UVEAL MELANOMATHE SOUTHAMPTON EXPERIENCE DR IOANNIS KARYDIS ASSOCIATE PROFESSOR IN MEDICAL ONCOLOGY UNIVERSITY OF SOUTHAMPTON AND SOUTHAMPTON UNIVERSITY HOSPITAL
UVEAL MELANOMA – BACKGROUND • Incidence 2-8/million in Europe • 400-450 new cases / year in UK
• 50% will develop metastatic disease within 15 years • Historic data: • Median expected survival 4-6 months • At 1 year post diagnosis of metastasis only 10-15% still alive without treatment
UVEAL MELANOMA – AN ORPHAN DISEASE • No effective molecular targeted treatments available • Chemo-resistant (ORR<10 % even with combination regimes) • Immunotherapies unproven
LIVER DIRECTED THERAPIES
WHY? • 85-95% will develop liver metastases • In >~ 50% liver is the only site of metastatic disease
• Less than 5-10% qualify for surgical resection • Imaging often underestimates extent of disease
• Uncontrolled liver disease often behaves aggressively • Immunotherapeutics less likely to work
OPTIONS? • Ablation modalities (MW/LITT/RFA/Cryo) • Comparable to surgery (~3y OS)
• Chemo- / Immuno- / Radioembolisation • RR <~20% , OS 9-20m
• Hepatic Chemoperfusion
UVEAL MELANOMA IN SOUTHAMPTON • 30-40 high risk UM patients a year referred for follow-up post treatment of primary tumour • Direct referrals from UK and abroad for management of metastatic disease • Ocular Melanoma Multidisciplinary team • Interventional radiologists • Medical Oncologists • Hepatobiliary Surgeons • Perfusionists Anaesthetists • Nurse Specialists
INTEGRATING LIVER DIRECTED AND SYSTEMIC MANAGEMENT Early diagnosis of metastatic disease Liver directed management Systemic treatment
• Serial imaging • 6 - monthly liver MRI
• Surgery • Melphalan PHP / TACE • SIRTS • Ipilimumab • Anti PD-1 agents • Clinical Trials
PERCUTANEOUS HEPATIC PERFUSION (“PHP”) Chemofiltration circuit
Hepatic vein & IVC Isolation
Hepatic Artery cannulation
WORK-UP FOR MELPHALAN PHP Accurate Staging Clinical Assessment Management plan
MRI liver, body CT Liver angio
Staging laparoscopy
CPET testing
Oncology & Anaesthetic Review
OM MDT
Final consultation with patient
THE SOUTHAMPTON EXPERIENCE • 25 patients received 43 cycles (median 2, range 1-4) • 2 treatments abandoned on day of procedure due to unsuitable anatomy on angiography
• Median length of stay: 4 days • range 3-8, though only 3 episodes were longer than 5 days
HEPATIC RESPONSE ASSESSMENT • Best hepatic response (by liver MRI): • Overall Response Rate (CR+PR):
37 %
• Disease control rate (CR+PR+SD):
83 %
• Median liver Progression Free Survival : 242 days Best liver Response
N (%)
Complete Response
1 (4%)
Partial Response
8 (33%)
Stable Disease >3 months
11 (46%)
Progressive Disease
4 (17%)
OUTCOMES • Median Survival : 511 days (17 months) • 12/25 patients still alive after a median of 315 days (~10.5 months) • 1 year survival rate ~ 65%
• Progression Free Survival • Median overall PFS ~ 182 days (~6 mo) • Median liver PFS ~ 242 days (~8 mo) • In 9/21 (~42%) cases systemic progression preceded liver progression.
COMPARATOR: PHASE III TRIAL
• Hepatic median PFS: 242 vs 245 days • Overall median PFS:
182 vs 186 days
• Median OS:
511 vs 301 days
From: Hughes et al, Ann Surg Onc Apr 2016, Vol 23, Issue 4, pp 1309–1319 “Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases”
WHAT ABOUT SIDE EFFECTS? Adverse Events
UHS
Phase III trial
G3-4 Neutropenia
7/25 (28%)
60/70 (86%)
Febrile neutropenia
2/25 (8%)
12/70 (17%)
G3-4 Anaemia
10/25 (40%)
44/70 (63%)
G3-4 Thrombocytopenia
7/25 (28%)
56/80 (80%)
Cardiac arrhythmias
2/25 (8%)
4/70 (6%)
Troponin rise
1/25 (4%)
6/70 (9%)
SEVERE NON-HAEMATOLOGICAL TOXICITIES • No treatment related fatalities • Immediate toxicities: • Cardiovascular : 3/25 •
1 case of pulmonary oedema
•
2 cases of cardiac arrhythmias
• Vascular access complication : 2/25 •
1 case of intraabdominal haemorrhage
•
1 case of IVC thrombus (with subsequent PE)
• Late toxicities • Thromboembolic (4/25) •
•
3 cases of PE, 1 DVT diagnosed within 3 months of procedure
1 case of G3 fatigue
NON-HAEMATOLOGICAL MILDMODERATE TOXICITIES • Mild abnormalities in liver function tests • common (32%) but resolve rapidly
• Other notable mild toxicities include: • Nausea / Vomiting ( 12% & 8% respectively) • Epigastric discomfort (12%) • Constipation (8%) • Mucositis/ Alopecia (4%)
HAEMATOLOGICAL TOXICITIES • Immediate haematological toxicities common but easily manageable: Grade
1
2
3
4
Anaemia
4 (16%)
10 (40%)
10 (40%)
0
Thrombocytopenia
5 (20%)
11 (44%)
3 (12%)
4 (16%)
Neutropenia
0
1(4%)
2 (8%)
5 (20%)
• 2 episodes of neutropenic sepsis were documented • Platelet and blood transfusions were needed in 19 (76%) and 13 (52%) respectively, typically in the peri/immediate post-procedure setting • There was 1 case of systemic coagulopathy (DIC) requiring extensive coagulation factor support
PROS/CONS OF M-PHP • PROS: • High hepatic disease control rates • Generally well tolerated in appropriately selected patients
• CONS • Risk of potentially life threatening complications • Technically demanding & expensive
BIG ISSUE • Lack of concrete evidence of survival benefit/ superiority versus alternatives
FOCUS TRIAL – WHY? • Phase 3 trial allowed crossover • -> survival benefit diluted, not statistically significant • In the absence of evidence from randomised clinical trials NHS funding extremely unlikely
• Since then – technique has improved • New Immunotherapies have also arrived! • <-> less effective in patients with uncontrolled liver disease
* Is M-PHP superior to current alternatives? *
• Randomised: • Melphalan PHP vs alternative Standard of Care (TACE/immunotherapy/chemotherapy)
• Inclusion criteria • Histologically proven & measurable liver metastatic disease • No previous intra-arterial hepatic therapy • No contraindication to Melphalan PHP
MELPHALAN CHEMOPERFUSION A TECHNIQUE AT CROSSROADS • Appropriate patient selection and optimised perioperative management have resulted in improved side-effect profile • Role in a rapidly developing field of multiple –potentially complementary – treatment approaches remains to be determined
SOUTHAMPTON PHP EXPERIENCE SUMMARY • Melphalan PHP can be delivered safely by an experienced multidisciplinary team in the UHS • Can provide significant benefits in a carefully selected group of patients as part of a multidisciplinary approach • Further research is needed to establish its place in the context of new systemic and especially immunotherapeutic treatment Randomised Phase III study now open for recruitment!
Current Position for OM patients in Scotland • Single Specialist Centre based at Gartnavel Hospital, Glasgow • Detached from other specialist centres in the UK • Only offered US as routine follow up/surveillance • GPs have little or no knowledge of OM to support patients with disease or challenge the position on surveillance
PETITION TO SCOTTISH PARLIAMENT • To provide OM patients in Scotland with best surveillance Options • Ensure enhanced Abdominal MRI with contrast are offered as standard for early detection of liver metastases • Ensure consistency across all NHS Regions • Allow Scottish patients the opportunity to become their own advocates and change the current position WHY are patients in Scotland being denied the option of MRI?
Prevalence â&#x20AC;&#x201C; Numbers of registrations for melanomas of the uveal tract and other sites within the eye for all ages/persons, Scotland 2010-2014 â&#x20AC;&#x201C; Source: Scottish Cancer Registry ISD Data extracted Dec 2016 Year
Uveal Tract
Other sites within the eye
2010
61
7
2011
49
4
2012
47
2
2013
46
3
2014
59
3
According to National Services Scotland, Glasgow see 35-40 patients per year with the remainder being seen by centres in England
Scottish Government Action BEATING CANCER – Ambition & Action –
strategy dedicated to improving Cancer Services across Scotland
EYE CANCER does not appear in this strategy document
Specialist Cancer Organisations submissions Cancer Research UK “Having consulted extensively within the charity – including with our Health Information, Public & Patient Involvement and Policy teams – we regret to inform that Cancer Research UK does not have an existing view on this specific issue, and is therefore unable to advise on the potential clinical implications of these tests being used on Ocular Melanoma sufferers in Scotland.”
MacMillan Cancer Support Scotland “Following discussion with various MacMillan colleagues we are at the moment not able to take a firm position on this issue – but would welcome the committee looking into gaining further evidence around how best to take forward better detection and treatment for people with Ocular Melanoma.”
Royal College of Ophthalmologist's â&#x20AC;&#x153;There is not enough evidence to suggest that if liver US is competently performed, 6 monthly MRI of the liver with contrast is indicated. In England, US is still the accepted mode of surveillance. MRI should however be used for high risk cases or when US detects an abnormality. There is national guidance from experts1 in the field and the college supports the view taken by Ocular Oncologists in the publication referenced until new evidence-base suggests a change is needed.â&#x20AC;? 1 - Reference: uveal Melanoma UK National Guidelines, European Journal of Cancer (2015) 51, 2404-2412
OcuMel UK – support our petition
• Some patients are informed of Risk others are not! • High Risk and “Not knowing” both cause anxiety. OM patients mental health is affected • Anxiety also stems from not trusting US • Low risk does not mean “No Risk therefore all should receive MRI
US vs MRI • English Uveal Melanoma Guidelines (2015) are accredited by NICE – guideline development group follow these guidelines, made recommendations and used expert opinion. Agreed on contrast enhanced MRI of liver with diffusion weight imaging • MRI has made it possible to evaluate treatments for metastases at earlier stages of disease
Southampton quotes • MRI gives images which one can go back to and review – much more difficult with US which is also very operator dependent • MRI is now high quality and contrast improves this looking at changes in behaviour and how the contrast medium behaves • Some areas of the liver are hard to image on US – depth of vision; overlay of lung tissue; size of patient. Some groups of patients can be assessed by a skilled US operator. In US you can only document what you can see NOT what you cannot see • If we go for interval scanning we should be using the best available test
• Cost • Clinic time • Travel distance or time for patient • Country of Residence
None of the above should discriminate against having MRI scanning
Scottish Ocular Oncology Centre Offers only US annually or 6 monthly States – Approach consistent with guidelines – very little evidence on which to base decisions on either frequency or duration of follow up – due to the lack evidence (linked to the rarity of OM) variation exists amongst 4 UK centres which is the appropriate surveillance to use! They state 2-3 other centres offer only US Follow NICE guidelines with a review due in 2019
Scottish Government state • Limited hospitals in England offer MRI • Commissioning for Quality and Innovation (CQUIN) group will set up a group to improve consistency in hospitals across the UK. Will share expertise to develop a UK wide guidance/recommendations for surveillance of OM patients. • There is insufficient evidence to change surveillance protocol from US to MRI • Scottish Ocular Oncology Service will undertake a study of metastatic patients to ascertain whether a delay in diagnosis was incurred due to use of US. This study will take some time due to the small number of patients in Scotland